Colorectal Cancer Biomarker Database (CBD2)

CBD2 curates and integrates colorectal cancer biomarker data with network analysis and polypharmacological treatment design capabilities.

Key Features:

• Biomarker Curation: CBD2 catalogs 1569 colorectal cancer biomarkers derived from DNA, RNA, protein, and other biological sources, spanning diagnostic, therapeutic, and prognostic clinical applications.
• Nonbiomarker Annotation: CBD2 incorporates entities identified as unsuitable for use as colorectal cancer biomarkers.
• Network Analysis: CBD2 enables investigation of visible and topological networks between biomarkers and identification of their relevant pathways.
• Polypharmacological Query: CBD2 supports querying of chemicals, drug combinations, or multiple targets to enable multidrug, multitarget, multipathway analyses for treatment design.

Scientific Applications:

• Biomarker Discovery and Validation: Researchers can access curated biomarker information across multiple molecular types and clinical contexts to identify potential colorectal cancer biomarkers.
• Network-Based Pathway Analysis: Users can investigate biomarker relationships and their associated pathways through topological network analysis.
• Polypharmacological Treatment Design: Researchers can perform multidrug, multitarget, and multipathway analyses to facilitate the design of combination therapies for colorectal cancer.

Methodology:

CBD2 was developed by curating newly reported biomarkers from the literature and building upon the previous CBD framework; specific computational methods for network construction and polypharmacological analysis are not detailed in the sources.